Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Products of "Bcr-Abl"
Sort by
Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formula:C29H27F3N6OPurity:100% - 99.29%Color and Shape:SolidMolecular weight:532.56Ref: TM-T3071
1mg35.00€2mg48.00€5mg70.00€10mg96.00€25mg210.00€50mg338.00€100mg535.00€1mL*10mM (DMSO)82.00€Imatinib Mesylate
CAS:Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,Formula:C29H31N7O·CH4SO3Purity:100% - 99.97%Color and Shape:White Crystalline PowderMolecular weight:589.71BCR-ABL-IN-1
CAS:BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Formula:C23H21F4N5OPurity:98%Color and Shape:SolidMolecular weight:459.44AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.Formula:C22H20F3N7OPurity:98.23%Color and Shape:SoildMolecular weight:455.44Ref: TM-T22552L
1mg34.00€2mg52.00€5mg116.00€10mg212.00€25mg359.00€50mg512.00€100mg695.00€200mg939.00€1mL*10mM (DMSO)134.00€Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurity:98% - 99.60%Color and Shape:SolidMolecular weight:532.56AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurity:98% - 99.37%Color and Shape:SolidMolecular weight:305.17BCR-ABL-IN-8
CAS:BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].Formula:C30H33N7O5Purity:98%Color and Shape:SolidMolecular weight:571.63Bosutinib hydrate
CAS:Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Formula:C26H31Cl2N5O4Purity:99.87%Color and Shape:SolidMolecular weight:548.46Dasatinib hydrochloride
CAS:Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).Formula:C22H27Cl2N7O2SPurity:99.88% - 99.98%Color and Shape:SolidMolecular weight:524.47DPH
CAS:DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formula:C18H13FN4O2Purity:99.72%Color and Shape:SolidMolecular weight:336.32GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purity:97.05% - 99.47%Color and Shape:SolidMolecular weight:547.53XL228
CAS:XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Formula:C22H31N9OPurity:99.07%Color and Shape:SolidMolecular weight:437.54Ref: TM-T17267
1mg56.00€2mg78.00€5mg99.00€10mg149.00€25mg258.00€50mg393.00€100mg582.00€1mL*10mM (DMSO)110.00€Nilotinib monohydrochloride monohydrate
CAS:Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosineFormula:C28H22F3N7O·HCl·H2OPurity:99.93%Color and Shape:SolidMolecular weight:583.99KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Formula:C20H20N4OPurity:98.43% - 99.89%Color and Shape:SolidMolecular weight:332.4Vodobatinib
CAS:Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.Formula:C27H20ClN3O2Purity:99.06% - 99.55%Color and Shape:SolidMolecular weight:453.92Ref: TM-T8882
1mg37.00€5mg79.00€10mg116.00€25mg212.00€50mg340.00€100mg528.00€500mg1,275.00€1mL*10mM (DMSO)87.00€Gypsogenin
CAS:Gypsogenin (639-14-5) is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.Formula:C30H46O4Purity:99.73%Color and Shape:SolidMolecular weight:470.68Ref: TM-T25476
1mg134.00€5mg315.00€10mg469.00€25mg748.00€50mg1,064.00€100mg1,415.00€1mL*10mM (DMSO)349.00€BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formula:C30H29F3N6O3Purity:100% - 95.05%Color and Shape:SolidMolecular weight:578.58Ref: TM-T4618
1mg62.00€2mg87.00€5mg119.00€10mg188.00€25mg350.00€50mg505.00€100mg730.00€1mL*10mM (DMSO)154.00€HG-7-86-01
CAS:HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).Formula:C28H21F3N6O2SPurity:99.07%Color and Shape:SolidMolecular weight:562.57Adaphostin
CAS:Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Formula:C24H27NO4Purity:97.31%Color and Shape:SolidMolecular weight:393.48cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formula:C24H27ClN6O4Color and Shape:SolidMolecular weight:498.96
